Loading organizations...
§ Private Profile · San Diego, CA, USA
Develops RNA genomics technologies and sequencing platforms to map RNA structures and binding proteins for RNA therapeutics
Based in San Diego, California, Eclipse Bioinnovations develops RNA genomics technologies and advanced next-generation sequencing platforms to map RNA structures and binding proteins for researchers. The company provides specialized tools like eCLIP-Seq and eSENSE dsRNA to global biotechnology and pharmaceutical clients developing RNA medicines, preclinical vaccines, and gene therapies, successfully partnering with over 100 distinct organizations. Operating from an 18,000-square-foot headquarters, the enterprise maintains a workforce of 10 to 50 employees. The firm raised $14 million in a June 2022 Series A financing round backed by institutional investors such as Alexandria Venture Investments, iGlobe, and Phoenix Venture Partners. Additionally, the organization receives federal grant funding from the NIH and features former Novartis chief executive officer Daniel Vasella on its corporate board of directors. Eclipse Bioinnovations was founded in 2017 by Peter Chu and Gene Yeo.
Eclipse Bioinnovations has raised $14.0M across 1 funding round.
Eclipse Bioinnovations has raised $14.0M in total across 1 funding round.
Eclipse Bioinnovations has raised $14.0M in total across 1 funding round.
Eclipse Bioinnovations's investors include Hallie Kuhn, iGlobe, Phoenix Venture Partners, Photon Venture Alpha.
Eclipse Bioinnovations has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 22, 2022 | $14M Series A | Hallie Kuhn, Iglobe | Phoenix Venture Partners, Photon Venture Alpha | Announced |